|
|
|
|
| LEADER |
01341nam a2200241 u 4500 |
| 001 |
EB002001149 |
| 003 |
EBX01000000000000001164050 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices
|h Elektronische Ressource
|b a review of the clinical effectiveness, cost-effectiveness and guidelines
|
| 260 |
|
|
|a [Ottawa, Ontario]
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 27 January 2016
|
| 300 |
|
|
|a 1 PDF file (28 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK343860
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a This Rapid Response report aims to review the clinical- and cost-effectiveness of telehealth for patients with hypertension, coronary artery disease (CAD), or conditions requiring implantable cardiac devices. Guidelines associated with the use of telehealth in the management of these conditions will also be examined
|